Avalon GloboCare Corp. (NASDAQ: AVCO) was founded in 2014 and is headquartered in Freehold, New Jersey, USA. It has 7 full-time employees and its subsidiaries. It is engaged in the integration and management of healthcare services and resources in the United States.
Avalon GloboCare Corp. (AVCO):
Avalon GloboCare provides medical-related consulting services and develops Avalon Cell and Avalon Rehab platforms, covering areas such as regenerative medicine, cell-based immunotherapy, exosome technology, and rehabilitation medicine.
Avalon GloboCare also develops proprietary diagnostic and therapeutic products using exosome technology; and sells and distributes proprietary exosome isolation systems and related products to hospitals, and provides development services for hospitals.
Furthermore, Avalon GloboCare owns and operates real estate.
Avalon GloboCare and Weill Cornell Medical College have established a strategic partnership to jointly develop technology and biological products for chimeric antigen receptor-T therapy.